Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIRA study of tocilizumab tapering and trough levels in rheumatoid arthritis
NL-OMON53280Phase 4Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Franciscus Gasthuis & Vlietland. Primary endpoints: Successful tapering after 12 months and Tocilizumab serum concentration range associated with maintained low disease activity. Started Sep 2024; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON53280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53280.